Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial. Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, et al. Blood 2026;147:2895-2904.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sharman JP, Laurenti L, Ferrant E, Casado Montero LF, et al. Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trial. Blood 2026;147:2895-2904.
PMID: 41770817